Deutsche Bank
NRIX icon

Deutsche Bank’s Nurix Therapeutics NRIX Stock Holding History

Deutsche Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Sell
151,453
-2,143,571
-93% -$36.5M ﹤0.01% 1539
2026
Q1 		$35.6M Sell
2,295,024
-191,768
-8% -$3.18M 0.01% 717
2025
Q4 		$47.2M Buy
2,486,792
+1,047,933
+73% +$15.1M 0.02% 650
2025
Q3 		$13.3M Buy
1,438,859
+1,069,981
+290% +$11.1M ﹤0.01% 969
2025
Q2 		$4.2M Sell
368,878
-11,270
-3% -$122K ﹤0.01% 1318
2025
Q1 		$4.52M Sell
380,148
-151,049
-28% -$2.53M ﹤0.01% 1291
2024
Q4 		$10M Sell
531,197
-323,485
-38% -$7.41M ﹤0.01% 1025
2024
Q3 		$19.2M Sell
854,682
-193,712
-18% -$4.39M 0.01% 843
2024
Q2 		$21.9M Sell
1,048,394
-450,974
-30% -$7.02M 0.01% 793
2024
Q1 		$22M Buy
1,499,368
+995,163
+197% +$10.7M 0.01% 785
2023
Q4 		$5.2M Buy
504,205
+484,610
+2,473% +$3.32M ﹤0.01% 1239
2023
Q3 		$154K Buy
19,595
+3,841
+24% +$35.1K ﹤0.01% 2938
2023
Q2 		$157K Sell
15,754
-12,659
-45% -$129K ﹤0.01% 3027
2023
Q1 		$252K Buy
28,413
+8,667
+44% +$90.3K ﹤0.01% 2896
2022
Q4 		$217K Buy
19,746
+310
+2% +$3.74K ﹤0.01% 2940
2022
Q3 		$253K Sell
19,436
-1,527
-7% -$24.2K ﹤0.01% 2804
2022
Q2 		$266K Buy
20,963
+3,011
+17% +$34.1K ﹤0.01% 2999
2022
Q1 		$252K Sell
17,952
-2,018
-10% -$35.8K ﹤0.01% 3128
2021
Q4 		$578K Buy
19,970
+677
+4% +$20.5K ﹤0.01% 2743
2021
Q3 		$578K Sell
19,293
-582
-3% -$18K ﹤0.01% 2929
2021
Q2 		$527K Buy
19,875
+4,130
+26% +$121K ﹤0.01% 3188
2021
Q1 		$490K Buy
15,745
+2,709
+21% +$102K ﹤0.01% 3115
2020
Q4 		$429K Buy
13,036
+7,105
+120% +$235K ﹤0.01% 3009
2020
Q3 		$207K Buy
+5,931
New +$149K ﹤0.01% 3193

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank's NRIX Position: Q2 2026 in Review

Deutsche Bank reduced its Nurix Therapeutics (NRIX) stake by 93% in Q2 2026, selling an estimated $36.5M and leaving 151,453 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Deutsche Bank first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $47.2M in Q4 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Deutsche Bank held 151,453 shares of Nurix Therapeutics worth $3.67M as of Q2 2026.
  • Deutsche Bank sold 2,143,571 Nurix Therapeutics shares in Q2 2026, an estimated $36.5M.
  • Nurix Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1539 holding.
  • Deutsche Bank first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Deutsche Bank's Nurix Therapeutics position peaked at $47.2M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.